MCM
DMAC icon

MAI Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

MAI Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61 Buy
+9
New +$71 ﹤0.01% 4833

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MAI Capital Management's DMAC Position: Q1 2026 in Review

MAI Capital Management opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 9 shares worth $61. The stake represents ﹤0.01% of the portfolio and ranks #4833 among its holdings.

98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • MAI Capital Management held 9 shares of DiaMedica Therapeutics worth $61 as of Q1 2026.
  • DiaMedica Therapeutics was a new MAI Capital Management position in Q1 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4833 holding.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.